Top

Published in:

01-12-2010 | NON-THEMATIC REVIEW

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Authors: Xueqing Sun, Guangcun Cheng, Mingang Hao, Jianghua Zheng, Xiaoming Zhou, Jian Zhang, Russell S. Taichman, Kenneth J. Pienta, Jianhua Wang

Published in: Cancer and Metastasis Reviews | Issue 4/2010

Abstract

Chemokines, small pro-inflammatory chemoattractant cytokines that bind to specific G-protein-coupled seven-span transmembrane receptors, are major regulators of cell trafficking and adhesion. The chemokine CXCL12 (also called stromal-derived factor-1) is an important α-chemokine that binds primarily to its cognate receptor CXCR4 and thus regulates the trafficking of normal and malignant cells. For many years, it was believed that CXCR4 was the only receptor for CXCL12. Yet, recent work has demonstrated that CXCL12 also binds to another seven-transmembrane span receptor called CXCR7. Our group and others have established critical roles for CXCR4 and CXCR7 on mediating tumor metastasis in several types of cancers, in addition to their contributions as biomarkers of tumor behavior as well as potential therapeutic targets. Here, we review the current concepts regarding the role of CXCL12 / CXCR4 / CXCR7 axis activation, which regulates the pattern of tumor growth and metastatic spread to organs expressing high levels of CXCL12 to develop secondary tumors. We also summarize recent therapeutic approaches to target these receptors and/or their ligands.

Vindrieux, D., Escobar, P., & Lazennec, G. (2009). Emerging roles of chemokines in prostate cancer. Endocrine-Related Cancer, 16(3), 663–673.PubMedCrossRef

Ransohoff, R. M. (2009). Chemokines and chemokine receptors: Standing at the crossroads of immunobiology and neurobiology. Immunity, 31(5), 711–721.PubMedCrossRef

Bieche, I., Chavey, C., Andrieu, C., Busson, M., Vacher, S., Le Corre, L., et al. (2007). Cxc chemokines located in the 4q21 region are up-regulated in breast cancer. Endocrine-Related Cancer, 14(4), 1039–1052.PubMedCrossRef

New, D. C., & Wong, Y. H. (2003). Cc chemokine receptor-coupled signalling pathways. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 35(9), 779–788.

Rot, A., & von Andrian, U. H. (2004). Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Annual Review of Immunology, 22, 891–928.PubMedCrossRef

Lazennec, G., & Richmond, A. (2010). Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol Med, 16(3), 133–144.PubMedCrossRef

Keeley, E. C., Mehrad, B., & Strieter, R. M. (2010). Cxc chemokines in cancer angiogenesis and metastases. Adv Cancer Res, 106, 91–111.PubMedCrossRef

Kruizinga, R. C., Bestebroer, J., Berghuis, P., de Haas, C. J., Links, T. P., de Vries, E. G., et al. (2009). Role of chemokines and their receptors in cancer. Current Pharmaceutical Design, 15(29), 3396–3416.PubMedCrossRef

Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6(1), 17–32.PubMedCrossRef

10.

Hartmann, T. N., Burger, M., & Burger, J. A. (2004). The role of adhesion molecules and chemokine receptor cxcr4 (cd184) in small cell lung cancer. Journal of Biological Regulators and Homeostatic Agents, 18(2), 126–130.PubMed

11.

Secchiero, P., Celeghini, C., Cutroneo, G., Di Baldassarre, A., Rana, R., & Zauli, G. (2000). Differential effects of stromal derived factor-1 alpha (sdf-1 alpha) on early and late stages of human megakaryocytic development. The Anatomical Record, 260(2), 141–147.PubMedCrossRef

12.

Wright, L. M., Maloney, W., Yu, X., Kindle, L., Collin-Osdoby, P., & Osdoby, P. (2005). Stromal cell-derived factor-1 binding to its chemokine receptor cxcr4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone, 36(5), 840–853.PubMedCrossRef

13.

Gillette, J. M., Larochelle, A., Dunbar, C. E., & Lippincott-Schwartz, J. (2009). Intercellular transfer to signalling endosomes regulates an ex vivo bone marrow niche. Nature Cell Biology, 11(3), 303–311.PubMedCrossRef

14.

Hayakawa, J., Migita, M., Ueda, T., Fukazawa, R., Adachi, K., Ooue, Y., et al. (2009). Dextran sulfate and stromal cell derived factor-1 promote cxcr4 expression and improve bone marrow homing efficiency of infused hematopoietic stem cells. Journal of Nippon Medical School, 76(4), 198–208.PubMedCrossRef

15.

Kyriakou, C., Rabin, N., Pizzey, A., Nathwani, A., & Yong, K. (2008). Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica, 93(10), 1457–1465.PubMedCrossRef

16.

Tashiro, K., Tada, H., Heilker, R., Shirozu, M., Nakano, T., & Honjo, T. (1993). Signal sequence trap: A cloning strategy for secreted proteins and type i membrane proteins. Science, 261(5121), 600–603.PubMedCrossRef

17.

Dettin, M., Pasquato, A., Scarinci, C., Zanchetta, M., De Rossi, A., & Di Bello, C. (2004). Anti-hiv activity and conformational studies of peptides derived from the c-terminal sequence of sdf-1. Journal of Medicinal Chemistry, 47(12), 3058–3064.PubMedCrossRef

18.

Janowski, M. (2009). Functional diversity of sdf-1 splicing variants. Cell Adhesion & Migration, 3(3), 243–249.CrossRef

19.

Kucia, M., Wojakowski, W., Reca, R., Machalinski, B., Gozdzik, J., Majka, M., et al. (2006). The migration of bone marrow-derived non-hematopoietic tissue-committed stem cells is regulated in an sdf-1-, hgf-, and life-dependent manner. Archivum Immunologiae et Therapiae Experimentalis (Warsz), 54(2), 121–135.CrossRef

20.

Yu, L., Cecil, J., Peng, S. B., Schrementi, J., Kovacevic, S., Paul, D., et al. (2006). Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene, 374, 174–179.PubMedCrossRef

21.

Neiva, K., Sun, Y. X., & Taichman, R. S. (2005). The role of osteoblasts in regulating hematopoietic stem cell activity and tumor metastasis. Brazilian Journal of Medical and Biological Research, 38(10), 1449–1454.PubMedCrossRef

22.

Jung, Y., Wang, J., Schneider, A., Sun, Y. X., Koh-Paige, A. J., Osman, N. I., et al. (2006). Regulation of sdf-1 (cxcl12) production by osteoblasts; a possible mechanism for stem cell homing. Bone, 38(4), 497–508.PubMedCrossRef

23.

Taichman, R. S., Cooper, C., Keller, E. T., Pienta, K. J., Taichman, N. S., & McCauley, L. K. (2002). Use of the stromal cell-derived factor-1/cxcr4 pathway in prostate cancer metastasis to bone. Cancer Research, 62(6), 1832–1837.PubMed

24.

Peled, A., Petit, I., Kollet, O., Magid, M., Ponomaryov, T., Byk, T., et al. (1999). Dependence of human stem cell engraftment and repopulation of nod/scid mice on cxcr4. Science, 283(5403), 845–848.PubMedCrossRef

25.

Ponomaryov, T., Peled, A., Petit, I., Taichman, R. S., Habler, L., Sandbank, J., et al. (2000). Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. Journal of Clinical Investigation, 106(11), 1331–1339.PubMedCrossRef

26.

Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., et al. (2002). G-csf induces stem cell mobilization by decreasing bone marrow sdf-1 and up-regulating cxcr4. Nature Immunology, 3(7), 687–694.PubMedCrossRef

27.

Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., et al. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through hif-1 induction of sdf-1. Natural Medicines, 10(8), 858–864.CrossRef

28.

Caruz, A., Samsom, M., Alonso, J. M., Alcami, J., Baleux, F., Virelizier, J. L., et al. (1998). Genomic organization and promoter characterization of human cxcr4 gene. FEBS Letters, 426(2), 271–278.PubMedCrossRef

29.

Gupta, S. K., & Pillarisetti, K. (1999). Cutting edge: Cxcr4-lo: Molecular cloning and functional expression of a novel human cxcr4 splice variant. Journal of Immunology, 163(5), 2368–2372.

30.

Wegner, S. A., Ehrenberg, P. K., Chang, G., Dayhoff, D. E., Sleeker, A. L., & Michael, N. L. (1998). Genomic organization and functional characterization of the chemokine receptor cxcr4, a major entry co-receptor for human immunodeficiency virus type 1. The Journal of Biological Chemistry, 273(8), 4754–4760.PubMedCrossRef

31.

Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I., & Littman, D. R. (1998). Function of the chemokine receptor cxcr4 in haematopoiesis and in cerebellar development. Nature, 393(6685), 595–599.PubMedCrossRef

32.

Feil, C., & Augustin, H. G. (1998). Endothelial cells differentially express functional cxc-chemokine receptor-4 (cxcr-4/fusin) under the control of autocrine activity and exogenous cytokines. Biochemical and Biophysical Research Communications, 247(1), 38–45.PubMedCrossRef

33.

Lazarini, F., Casanova, P., Tham, T. N., De Clercq, E., Arenzana-Seisdedos, F., Baleux, F., et al. (2000). Differential signalling of the chemokine receptor cxcr4 by stromal cell-derived factor 1 and the hiv glycoprotein in rat neurons and astrocytes. The European Journal of Neuroscience, 12(1), 117–125.PubMedCrossRef

34.

Aiuti, A., Tavian, M., Cipponi, A., Ficara, F., Zappone, E., Hoxie, J., et al. (1999). Expression of cxcr4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. European Journal of Immunology, 29(6), 1823–1831.PubMedCrossRef

35.

Aiuti, A., Webb, I. J., Bleul, C., Springer, T., & Gutierrez-Ramos, J. C. (1997). The chemokine sdf-1 is a chemoattractant for human cd34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of cd34+ progenitors to peripheral blood. The Journal of Experimental Medicine, 185(1), 111–120.PubMedCrossRef

36.

Doitsidou, M., Reichman-Fried, M., Stebler, J., Koprunner, M., Dorries, J., Meyer, D., et al. (2002). Guidance of primordial germ cell migration by the chemokine sdf-1. Cell, 111(5), 647–659.PubMedCrossRef

37.

Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., et al. (1996). Defects of b-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the cxc chemokine pbsf/sdf-1. Nature, 382(6592), 635–638.PubMedCrossRef

38.

Lee, R. L., Westendorf, J., & Gold, M. R. (2007). Differential role of reactive oxygen species in the activation of mitogen-activated protein kinases and akt by key receptors on b-lymphocytes: Cd40, the b cell antigen receptor, and cxcr4. Journal of Cell Communication and Signaling, 1(1), 33–43.PubMedCrossRef

39.

Lu, D. Y., Tang, C. H., Yeh, W. L., Wong, K. L., Lin, C. P., Chen, Y. H., et al. (2009). Sdf-1alpha up-regulates interleukin-6 through cxcr4, pi3k/akt, erk, and nf-kappab-dependent pathway in microglia. European Journal of Pharmacology, 613(1–3), 146–154.PubMedCrossRef

40.

Princen, K., Hatse, S., Vermeire, K., De Clercq, E., & Schols, D. (2003). Evaluation of sdf-1/cxcr4-induced ca2+ signaling by fluorometric imaging plate reader (flipr) and flow cytometry. Cytometry. Part A, 51(1), 35–45.CrossRef

41.

Roland, J., Murphy, B. J., Ahr, B., Robert-Hebmann, V., Delauzun, V., Nye, K. E., et al. (2003). Role of the intracellular domains of cxcr4 in sdf-1-mediated signaling. Blood, 101(2), 399–406.PubMedCrossRef

42.

Balkwill, F. (2004). Cancer and the chemokine network. Nature Reviews. Cancer, 4(7), 540–550.PubMedCrossRef

43.

Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50–56.PubMedCrossRef

44.

Scotton, C. J., Wilson, J. L., Milliken, D., Stamp, G., & Balkwill, F. R. (2001). Epithelial cancer cell migration: A role for chemokine receptors? Cancer Research, 61(13), 4961–4965.PubMed

45.

Zagzag, D., Lukyanov, Y., Lan, L., Ali, M. A., Esencay, M., Mendez, O., et al. (2006). Hypoxia-inducible factor 1 and vegf upregulate cxcr4 in glioblastoma: Implications for angiogenesis and glioma cell invasion. Laboratory Investigation, 86(12), 1221–1232.PubMedCrossRef

46.

Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., et al. (2006). A novel chemokine receptor for sdf-1 and i-tac involved in cell survival, cell adhesion, and tumor development. The Journal of Experimental Medicine, 203(9), 2201–2213.PubMedCrossRef

47.

Balabanian, K., Lagane, B., Infantino, S., Chow, K. Y., Harriague, J., Moepps, B., et al. (2005). The chemokine sdf-1/cxcl12 binds to and signals through the orphan receptor rdc1 in t lymphocytes. The Journal of Biological Chemistry, 280(42), 35760–35766.PubMedCrossRef

48.

Libert, F., Parmentier, M., Lefort, A., Dumont, J. E., & Vassart, G. (1990). Complete nucleotide sequence of a putative G protein coupled receptor: Rdc1. Nucleic Acids Research, 18(7), 1917.PubMedCrossRef

49.

Jones, S. W., Brockbank, S. M., Mobbs, M. L., Le Good, N. J., Soma-Haddrick, S., Heuze, A. J., et al. (2006). The orphan G-protein coupled receptor rdc1: Evidence for a role in chondrocyte hypertrophy and articular cartilage matrix turnover. Osteoarthritis and Cartilage, 14(6), 597–608.PubMedCrossRef

50.

Raggo, C., Ruhl, R., McAllister, S., Koon, H., Dezube, B. J., Fruh, K., et al. (2005). Novel cellular genes essential for transformation of endothelial cells by kaposi's sarcoma-associated herpesvirus. Cancer Research, 65(12), 5084–5095.PubMedCrossRef

51.

Martinez, A., Kapas, S., Miller, M. J., Ward, Y., & Cuttitta, F. (2000). Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic beta-cells. Endocrinology, 141(1), 406–411.PubMedCrossRef

52.

Tripathi, V., Verma, R., Dinda, A., Malhotra, N., Kaur, J., & Luthra, K. (2009). Differential expression of rdc1/cxcr7 in the human placenta. Journal of Clinical Immunology, 29(3), 379–386.PubMedCrossRef

53.

Miao, Z., Luker, K. E., Summers, B. C., Berahovich, R., Bhojani, M. S., Rehemtulla, A., et al. (2007). Cxcr7 (rdc1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proceedings of the National Academy of Sciences of the United States of America, 104(40), 15735–15740.PubMedCrossRef

54.

Wang, J., Shiozawa, Y., Wang, Y., Jung, Y., Pienta, K. J., Mehra, R., et al. (2008). The role of cxcr7/rdc1 as a chemokine receptor for cxcl12/sdf-1 in prostate cancer. The Journal of Biological Chemistry, 283(7), 4283–4294.PubMedCrossRef

55.

Begley, L. A., MacDonald, J. W., Day, M. L., & Macoska, J. A. (2007). Cxcl12 activates a robust transcriptional response in human prostate epithelial cells. The Journal of Biological Chemistry, 282(37), 26767–26774.PubMedCrossRef

56.

Rajagopal, S., Kim, J., Ahn, S., Craig, S., Lam, C. M., Gerard, N. P., et al. (2010). Beta-arrestin- but not G protein-mediated signaling by the “Decoy” Receptor cxcr7. Proc Natl Acad Sci U S A, 107(2), 628–632.PubMedCrossRef

57.

Boldajipour, B., Mahabaleshwar, H., Kardash, E., Reichman-Fried, M., Blaser, H., Minina, S., et al. (2008). Control of chemokine-guided cell migration by ligand sequestration. Cell, 132(3), 463–473.PubMedCrossRef

58.

Dambly-Chaudiere, C., Cubedo, N., & Ghysen, A. (2007). Control of cell migration in the development of the posterior lateral line: Antagonistic interactions between the chemokine receptors cxcr4 and cxcr7/rdc1. BMC Developmental Biology, 7, 23.PubMedCrossRef

59.

Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., & Lagane, B. (2009). Cxcr7 heterodimerizes with cxcr4 and regulates cxcl12-mediated G protein signaling. Blood, 113(24), 6085–6093.PubMedCrossRef

60.

Sierro, F., Biben, C., Martinez-Munoz, L., Mellado, M., Ransohoff, R. M., Li, M., et al. (2007). Disrupted cardiac development but normal hematopoiesis in mice deficient in the second cxcl12/sdf-1 receptor, cxcr7. Proceedings of the National Academy of Sciences of the United States of America, 104(37), 14759–14764.PubMedCrossRef

61.

Hartmann, T. N., Grabovsky, V., Pasvolsky, R., Shulman, Z., Buss, E. C., Spiegel, A., et al. (2008). A crosstalk between intracellular cxcr7 and cxcr4 involved in rapid cxcl12-triggered integrin activation but not in chemokine-triggered motility of human t lymphocytes and cd34+ cells. Journal of Leukocyte Biology, 84(4), 1130–1140.PubMedCrossRef

62.

Kalatskaya, I., Berchiche, Y. A., Gravel, S., Limberg, B. J., Rosenbaum, J. S., & Heveker, N. (2009). Amd3100 is a cxcr7 ligand with allosteric agonist properties. Molecular Pharmacology, 75(5), 1240–1247.PubMedCrossRef

63.

Luker, K. E., Gupta, M., Steele, J. M., Foerster, B. R., & Luker, G. D. (2009). Imaging ligand-dependent activation of cxcr7. Neoplasia, 11(10), 1022–1035.PubMed

64.

Fernandis, A. Z., Cherla, R. P., Chernock, R. D., & Ganju, R. K. (2002). Cxcr4/ccr5 down-modulation and chemotaxis are regulated by the proteasome pathway. The Journal of Biological Chemistry, 277(20), 18111–18117.PubMedCrossRef

65.

Sun, Y. X., Schneider, A., Jung, Y., Wang, J., Dai, J., Cook, K., et al. (2005). Skeletal localization and neutralization of the sdf-1(cxcl12)/cxcr4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research, 20(2), 318–329.PubMedCrossRef

66.

Engl, T., Relja, B., Marian, D., Blumenberg, C., Muller, I., Beecken, W. D., et al. (2006). Cxcr4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia, 8(4), 290–301.PubMedCrossRef

67.

Kukreja, P., Abdel-Mageed, A. B., Mondal, D., Liu, K., & Agrawal, K. C. (2005). Up-regulation of cxcr4 expression in pc-3 cells by stromal-derived factor-1alpha (cxcl12) increases endothelial adhesion and transendothelial migration: Role of mek/erk signaling pathway-dependent nf-kappab activation. Cancer Research, 65(21), 9891–9898.PubMedCrossRef

68.

Sun, Y. X., Wang, J., Shelburne, C. E., Lopatin, D. E., Chinnaiyan, A. M., Rubin, M. A., et al. (2003). Expression of cxcr4 and cxcl12 (sdf-1) in human prostate cancers (pca) in vivo. Journal of Cellular Biochemistry, 89(3), 462–473.PubMedCrossRef

69.

Darash-Yahana, M., Pikarsky, E., Abramovitch, R., Zeira, E., Pal, B., Karplus, R., et al. (2004). Role of high expression levels of cxcr4 in tumor growth, vascularization, and metastasis. The FASEB Journal, 18(11), 1240–1242.PubMed

70.

Wang, J., Sun, Y., Song, W., Nor, J. E., Wang, C. Y., & Taichman, R. S. (2005). Diverse signaling pathways through the sdf-1/cxcr4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cellular Signalling, 17(12), 1578–1592.PubMedCrossRef

71.

Wang, J., Dai, J., Jung, Y., Wei, C. L., Wang, Y., Havens, A. M., et al. (2007). A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Research, 67(1), 149–159.PubMedCrossRef

72.

Zhao, H., & Peehl, D. M. (2009). Tumor-promoting phenotype of cd90hi prostate cancer-associated fibroblasts. The Prostate, 69(9), 991–1000.PubMedCrossRef

73.

Ratajczak, M. Z., Reca, R., Wysoczynski, M., Yan, J., & Ratajczak, J. (2006). Modulation of the sdf-1-cxcr4 axis by the third complement component (c3)—Implications for trafficking of cxcr4+ stem cells. Experimental Hematology, 34(8), 986–995.PubMedCrossRef

74.

Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313–323.PubMedCrossRef

75.

Mazzinghi, B., Ronconi, E., Lazzeri, E., Sagrinati, C., Ballerini, L., Angelotti, M. L., et al. (2008). Essential but differential role for cxcr4 and cxcr7 in the therapeutic homing of human renal progenitor cells. The Journal of Experimental Medicine, 205(2), 479–490.PubMedCrossRef

76.

Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordon-Cardo, C., et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537–549.PubMedCrossRef

77.

Liang, Z., Yoon, Y., Votaw, J., Goodman, M. M., Williams, L., & Shim, H. (2005). Silencing of cxcr4 blocks breast cancer metastasis. Cancer Research, 65(3), 967–971.PubMed

78.

Ueda, Y., Neel, N. F., Schutyser, E., Raman, D., & Richmond, A. (2006). Deletion of the cooh-terminal domain of cxc chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Cancer Research, 66(11), 5665–5675.PubMedCrossRef

79.

Holland, J. D., Kochetkova, M., Akekawatchai, C., Dottore, M., Lopez, A., & McColl, S. R. (2006). Differential functional activation of chemokine receptor cxcr4 is mediated by G proteins in breast cancer cells. Cancer Research, 66(8), 4117–4124.PubMedCrossRef

80.

Fulton, A. M. (2009). The chemokine receptors cxcr4 and cxcr3 in cancer. Current Oncology Reports, 11(2), 125–131.PubMedCrossRef

81.

Akekawatchai, C., Holland, J. D., Kochetkova, M., Wallace, J. C., & McColl, S. R. (2005). Transactivation of cxcr4 by the insulin-like growth factor-1 receptor (igf-1r) in human mda-mb-231 breast cancer epithelial cells. The Journal of Biological Chemistry, 280(48), 39701–39708.PubMedCrossRef

82.

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated sdf-1/cxcl12 secretion. Cell, 121(3), 335–348.PubMedCrossRef

83.

Razmkhah, M., Talei, A. R., Doroudchi, M., Khalili-Azad, T., & Ghaderi, A. (2005). Stromal cell-derived factor-1 (sdf-1) alleles and susceptibility to breast carcinoma. Cancer Letters, 225(2), 261–266.PubMedCrossRef

84.

Cabioglu, N., Summy, J., Miller, C., Parikh, N. U., Sahin, A. A., Tuzlali, S., et al. (2005). Cxcl-12/stromal cell-derived factor-1alpha transactivates her2-neu in breast cancer cells by a novel pathway involving src kinase activation. Cancer Research, 65(15), 6493–6497.PubMedCrossRef

85.

Salmaggi, A., Maderna, E., Calatozzolo, C., Gaviani, P., Canazza, A., Milanesi, I., et al. (2009). Cxcl12, cxcr4 and cxcr7 expression in brain metastases. Cancer Biology & Therapy, 8(17), 1608–1614.CrossRef

86.

Burger, J. A., & Kipps, T. J. (2006). Cxcr4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107(5), 1761–1767.PubMedCrossRef

87.

Burger, M., Glodek, A., Hartmann, T., Schmitt-Graff, A., Silberstein, L. E., Fujii, N., et al. (2003). Functional expression of cxcr4 (cd184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene, 22(50), 8093–8101.PubMedCrossRef

88.

Hartmann, T. N., Burger, J. A., Glodek, A., Fujii, N., & Burger, M. (2005). Cxcr4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (sclc) cells. Oncogene, 24(27), 4462–4471.PubMedCrossRef

89.

Su, L. P., Zhang, J. P., Xu, H. B., Chen, J., Wang, Y., & Xiong, S. D. (2005). the role of cxcr4 in lung cancer metastasis and its possible mechanism. Zhonghua Yi Xue Za Zhi, 85(17), 1190–1194.PubMed

90.

Kijima, T., Maulik, G., Ma, P. C., Tibaldi, E. V., Turner, R. E., Rollins, B., et al. (2002). Regulation of cellular proliferation, cytoskeletal function, and signal transduction through cxcr4 and c-kit in small cell lung cancer cells. Cancer Research, 62(21), 6304–6311.PubMed

91.

Phillips, R. J., Mestas, J., Gharaee-Kermani, M., Burdick, M. D., Sica, A., Belperio, J. A., et al. (2005). Epidermal growth factor and hypoxia-induced expression of cxc chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/pten/akt/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. The Journal of Biological Chemistry, 280(23), 22473–22481.PubMedCrossRef

92.

Iwakiri, S., Mino, N., Takahashi, T., Sonobe, M., Nagai, S., Okubo, K., et al. (2009). Higher expression of chemokine receptor cxcr7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer, 115(11), 2580–2593.PubMedCrossRef

93.

Billadeau, D. D., Chatterjee, S., Bramati, P., Sreekumar, R., Shah, V., Hedin, K., et al. (2006). Characterization of the cxcr4 signaling in pancreatic cancer cells. International Journal of Gastrointestinal Cancer, 37(4), 110–119.PubMed

94.

Mori, T., Doi, R., Koizumi, M., Toyoda, E., Ito, D., Kami, K., et al. (2004). Cxcr4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Molecular Cancer Therapeutics, 3(1), 29–37.PubMed

95.

Koshiba, T., Hosotani, R., Miyamoto, Y., Ida, J., Tsuji, S., Nakajima, S., et al. (2000). Expression of stromal cell-derived factor 1 and cxcr4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clinical Cancer Research, 6(9), 3530–3535.PubMed

96.

Marchesi, F., Monti, P., Leone, B. E., Zerbi, A., Vecchi, A., Piemonti, L., et al. (2004). Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional cxcr4. Cancer Research, 64(22), 8420–8427.PubMedCrossRef

97.

Gao, Z., Wang, X., Wu, K., Zhao, Y., & Hu, G. (2010). Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/cxcr4 axis. Pancreatology, 10(2–3), 186–193.PubMedCrossRef

98.

Marechal, R., Demetter, P., Nagy, N., Berton, A., Decaestecker, C., Polus, M., et al. (2009). High expression of cxcr4 may predict poor survival in resected pancreatic adenocarcinoma. British Journal of Cancer, 100(9), 1444–1451.PubMedCrossRef

99.

Jankowski, K., Kucia, M., Wysoczynski, M., Reca, R., Zhao, D., Trzyna, E., et al. (2003). Both hepatocyte growth factor (hgf) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only hgf enhances their resistance to radiochemotherapy. Cancer Research, 63(22), 7926–7935.PubMed

100.

Balkwill, F. (2004). The significance of cancer cell expression of the chemokine receptor cxcr4. Seminars in Cancer Biology, 14(3), 171–179.PubMedCrossRef

101.

Bertolini, F., Dell’Agnola, C., Mancuso, P., Rabascio, C., Burlini, A., Monestiroli, S., et al. (2002). Cxcr4 neutralization, a novel therapeutic approach for non-Hodgkin’s lymphoma. Cancer Research, 62(11), 3106–3112.PubMed

102.

Scotton, C. J., Wilson, J. L., Scott, K., Stamp, G., Wilbanks, G. D., Fricker, S., et al. (2002). Multiple actions of the chemokine cxcl12 on epithelial tumor cells in human ovarian cancer. Cancer Research, 62(20), 5930–5938.PubMed

103.

Zhou, Y., Larsen, P. H., Hao, C., & Yong, V. W. (2002). Cxcr4 is a major chemokine receptor on glioma cells and mediates their survival. The Journal of Biological Chemistry, 277(51), 49481–49487.PubMedCrossRef

104.

Rubin, J. B., Kung, A. L., Klein, R. S., Chan, J. A., Sun, Y., Schmidt, K., et al. (2003). A small-molecule antagonist of cxcr4 inhibits intracranial growth of primary brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 100(23), 13513–13518.PubMedCrossRef

105.

Sehgal, A., Keener, C., Boynton, A. L., Warrick, J., & Murphy, G. P. (1998). Cxcr-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. Journal of Surgical Oncology, 69(2), 99–104.PubMedCrossRef

106.

Kim, J., Mori, T., Chen, S. L., Amersi, F. F., Martinez, S. R., Kuo, C., et al. (2006). Chemokine receptor cxcr4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Annals of Surgery, 244(1), 113–120.PubMedCrossRef

107.

Geminder, H., Sagi-Assif, O., Goldberg, L., Meshel, T., Rechavi, G., Witz, I. P., et al. (2001). A possible role for cxcr4 and its ligand, the cxc chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. Journal of Immunology, 167(8), 4747–4757.

108.

Scala, S., Ottaiano, A., Ascierto, P. A., Cavalli, M., Simeone, E., Giuliano, P., et al. (2005). Expression of cxcr4 predicts poor prognosis in patients with malignant melanoma. Clinical Cancer Research, 11(5), 1835–1841.PubMedCrossRef

109.

Zeelenberg, I. S., Ruuls-Van Stalle, L., & Roos, E. (2003). The chemokine receptor cxcr4 is required for outgrowth of colon carcinoma micrometastases. Cancer Research, 63(13), 3833–3839.PubMed

110..

Grymula, K., Tarnowski, M., Wysoczynski, M., Drukala, J., Barr, F. G., Ratajczak, J., et al. (2010) Overlapping and distinct role of cxcr7-sdf-1/itac and cxcr4-sdf-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer (in press).

111.

Libura, J., Drukala, J., Majka, M., Tomescu, O., Navenot, J. M., Kucia, M., et al. (2002). Cxcr4-sdf-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood, 100(7), 2597–2606.PubMedCrossRef

112.

Tarnowski, M., Grymula, K., Reca, R., Jankowski, K., Maksym, R., Tarnowska, J., et al. (2010). Regulation of expression of stromal-derived factor-1 receptors: Cxcr4 and cxcr7 in human rhabdomyosarcomas. Mol Cancer Res, 8(1), 1–14.PubMedCrossRef

113.

Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., et al. (2003). Interaction between leukemic-cell vla-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Natural Medicines, 9(9), 1158–1165.CrossRef

114.

Sanz-Rodriguez, F., Hidalgo, A., & Teixido, J. (2001). Chemokine stromal cell-derived factor-1alpha modulates vla-4 integrin-mediated multiple myeloma cell adhesion to cs-1/fibronectin and vcam-1. Blood, 97(2), 346–351.PubMedCrossRef

115.

Dvorak, H. F. (1986). Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England journal of medicine, 315(26), 1650–1659.PubMedCrossRef

116.

Horgan, K., Jones, D. L., & Mansel, R. E. (1987). Mitogenicity of human fibroblasts in vivo for human breast cancer cells. The British Journal of Surgery, 74(3), 227–229.PubMedCrossRef

117.

Ronnov-Jessen, L., Petersen, O. W., Koteliansky, V. E., & Bissell, M. J. (1995). The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. The Journal of clinical investigation, 95(2), 859–873.PubMedCrossRef

118.

Clarke, M. F., & Fuller, M. (2006). Stem cells and cancer: Two faces of eve. Cell, 124(6), 1111–1115.PubMedCrossRef

119.

Li, L., & Neaves, W. B. (2006). Normal stem cells and cancer stem cells: The niche matters. Cancer Research, 66(9), 4553–4557.PubMedCrossRef

120.

Polyak, K., & Hahn, W. C. (2006). Roots and stems: Stem cells in cancer. Natural Medicines, 12(3), 296–300.CrossRef

121.

Rak, J. (2006). Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis? Medical Hypotheses, 66(3), 601–604.PubMedCrossRef

122.

Yilmaz, O. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., et al. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature, 441(7092), 475–482.PubMedCrossRef

123.

Begley, L., Monteleon, C., Shah, R. B., Macdonald, J. W., & Macoska, J. A. (2005). Cxcl12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell, 4(6), 291–298.PubMedCrossRef

124.

Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). Vegfr1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820–827.PubMedCrossRef

125.

Houshmand, P., & Zlotnik, A. (2003). Targeting tumor cells. Current Opinion in Cell Biology, 15(5), 640–644.PubMedCrossRef

126.

Ao, M., Franco, O. E., Park, D., Raman, D., Williams, K., & Hayward, S. W. (2007). Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Research, 67(9), 4244–4253.PubMedCrossRef

127.

Zhang, L., Yeger, H., Das, B., Irwin, M. S., & Baruchel, S. (2007). Tissue microenvironment modulates cxcr4 expression and tumor metastasis in neuroblastoma. Neoplasia, 9(1), 36–46.PubMedCrossRef

128.

Donahue, R. E., Jin, P., Bonifacino, A. C., Metzger, M. E., Ren, J., Wang, E., et al. (2009). Plerixafor (amd3100) and granulocyte colony-stimulating factor (g-csf) mobilize different cd34+ cell populations based on global gene and microrna expression signatures. Blood, 114(12), 2530–2541.PubMedCrossRef

129.

Kim, S. Y., Lee, C. H., Midura, B. V., Yeung, C., Mendoza, A., Hong, S. H., et al. (2008). Inhibition of the cxcr4/cxcl12 chemokine pathway reduces the development of murine pulmonary metastases. Clinical & Experimental Metastasis, 25(3), 201–211.CrossRef

130.

Porvasnik, S., Sakamoto, N., Kusmartsev, S., Eruslanov, E., Kim, W. J., Cao, W., et al. (2009). Effects of cxcr4 antagonist ctce-9908 on prostate tumor growth. The Prostate, 69(13), 1460–1469.PubMedCrossRef

131.

Richert, M. M., Vaidya, K. S., Mills, C. N., Wong, D., Korz, W., Hurst, D. R., et al. (2009). Inhibition of cxcr4 by ctce-9908 inhibits breast cancer metastasis to lung and bone. Oncology Reports, 21(3), 761–767.PubMed

132.

Hojo, S., Koizumi, K., Tsuneyama, K., Arita, Y., Cui, Z., Shinohara, K., et al. (2007). High-level expression of chemokine cxcl16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Research, 67(10), 4725–4731.PubMedCrossRef

133.

Wysoczynski, M., Kucia, M., Ratajczak, J., & Ratajczak, M. Z. (2007). Cleavage fragments of the third complement component (c3) enhance stromal derived factor-1 (sdf-1)-mediated platelet production during reactive postbleeding thrombocytosis. Leukemia, 21(5), 973–982.PubMed

134.

Wysoczynski, M., Miekus, K., Jankowski, K., Wanzeck, J., Bertolone, S., Janowska-Wieczorek, A., et al. (2007). Leukemia inhibitory factor: A newly identified metastatic factor in rhabdomyosarcomas. Cancer Research, 67(5), 2131–2140.PubMedCrossRef

135.

McGrath, K. E., Koniski, A. D., Maltby, K. M., McGann, J. K., & Palis, J. (1999). Embryonic expression and function of the chemokine sdf-1 and its receptor, cxcr4. Developmental Biology, 213(2), 442–456.PubMedCrossRef

136.

Mohle, R., Moore, M. A., Nachman, R. L., & Rafii, S. (1997). Transendothelial migration of cd34+ and mature hematopoietic cells: An in vitro study using a human bone marrow endothelial cell line. Blood, 89(1), 72–80.PubMed

Title: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
Authors: Xueqing Sun
Guangcun Cheng
Mingang Hao
Jianghua Zheng
Xiaoming Zhou
Jian Zhang
Russell S. Taichman
Kenneth J. Pienta
Jianhua Wang
Publication date: 01-12-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9256-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Expression of tenascin-C and its isoforms in the breast

The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network

Feedback regulation of proteasome gene expression and its implications in cancer therapy

DNA repair pathways and their implication in cancer treatment

Regulatory T cells and breast cancer: implications for immunopathogenesis

Distant metastases do not metastasize

Keynote webinar | Spotlight on antibody–drug conjugates in cancer